SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending following a strong earnings report that showcased robust revenue growth and adjusted net income reaching breakeven, signaling strong execution in the AI infrastructure sector. The community is actively discussing these impressive results, particularly advanced negotiations for substantial new hyperscaler capacity, even as perplexing price movements lead to debates about market manipulation versus a prime buying opportunity. This focus on rapid expansion and growing demand for AI data centers underpins strong long-term sentiment.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending amid intense, politically charged discussions surrounding a controversial ICE-involved shooting in Minneapolis that resulted in a woman's death. Community members are sharply divided, with some echoing former President Trump's defense of the agent's actions as justified, while others are condemning it as murder and demanding accountability. This polarizing event is fueling fervent debate among commentators and impacting broader conversations around the stock.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is trending due to a political announcement targeting institutional purchases of single-family homes, triggering a significant sell-off and intense debate. Many in the community believe this news is actually bullish for Opendoor, arguing its iBuying model facilitates individual homeownership and will benefit from reduced institutional competition. However, others remain concerned, leading to divided perspectives on the company's future trajectory despite the CEO's clarifying statements.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX NASDAQ is trending amidst fervent community discussion centered on its extremely low share float and high short interest, leading to strong expectations of a potential short squeeze. Traders are actively comparing its setup to past high-volatility runners, with many anticipating substantial price appreciation while some express caution regarding potential dilution and the stock's historical volatility. The company's blockchain-based Plastic Cycle Token and digital DNA technology provide an underlying narrative for long-term potential.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp (OMER) is a major talking point after receiving FDA approval for Yartemlea, the first treatment for transplant-associated thrombotic microangiopathy, with its market launch quickly following. The community is actively discussing the drug's projected high per-patient treatment cost and its potential to become a standard of care, driving considerable excitement about future revenue and potential analyst upgrades.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending due to its exceptionally active community passionately championing the "OG meme" narrative of Rage Comics, positioning it as the foundational "meme reset" for an upcoming market cycle. This dedicated base is consistently building out an ecosystem with tools like RageMaker and RageGames. The community expresses strong conviction for significant long-term growth and leadership in the meme coin space, urging others to "Return to the Memes" and "Rage On."

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems (OSS) is trending following a pre-production order for GPU-accelerated compute systems aimed at enhancing situational awareness in U.S. Army combat vehicles, alongside a strategic asset sale to focus on core AI/edge compute. The community is buzzing with anticipation for a larger defense contract, fueled by the company's strong fundamentals, recent profitability, and perceived undervaluation in the rapidly growing AI and defense sectors.

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Immuneering Corp - Ordinary Shares Class A

Immuneering Corp

Immuneering is trending following the release of updated data for its pancreatic cancer treatment, showing a significant improvement in overall survival compared to the historical benchmark. Community perspectives are notably divided; many highlight the strong clinical benefit and improved quality of life, while others express disappointment that the reported 64% survival rate did not meet elevated market expectations. This mixed reaction is driving conversation around the stock's valuation, potential acquisition interest, and its robust funding for upcoming pivotal trials, despite comparisons to other oncology therapies.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martin is experiencing heightened trading activity driven by contrasting announcements from former President Trump, initially facing sell-offs on proposed dividend restrictions before surging on calls for a substantially increased military budget. This market volatility is compounded by news of a significant agreement to triple PAC-3 missile production, sparking community debate over market influence and defense sector growth.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is generating significant buzz following reports that JPMorgan has sealed a deal to take over its credit card operations, a move largely welcomed by the community. Despite this, the stock is noticeably lagging the broader market, triggering frustration among investors who are questioning Apple's innovation trajectory, particularly concerning AI and the initial reception of its new headset. Traders are keenly watching for support levels, debating whether the recent dip offers a prime buying opportunity or signals further weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The winding down of the said activities will impact about 365 employees across regions including Europe, the U.S. and China, the company said.&nbsp;</li><li>It will also result in the shut down of sites in the Netherlands, Switzerland, U.S. and China.</li><li>Galapagos CFO Aaron Cox had said in November that the company expects to be cash flow neutral to positive by the end of 2026 if the wind down is implemented.</li></ul> Galapagos NV (GLPG) on Monday announced that its Board of Directors has decided to initiate the wind-down of the company’s cell therapy activities, sending shares up 6% in Monday’s after hours trading.The company had announced its intent to wind down the activities after a strategic review and sale process in October but had held on acting on it until it completed communicating with work councils in the Belgium and Netherlands. The winding down of the said activities will impact about 365 employees across regions including Europe, the U.S. and China, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/05/3213177/0/en/Galapagos-Announces-Board-Decision-to-Initiate-Wind-Down-of-Cell-Therapy-Activities.html">said</a>.It will also result in the shut down of sites in the Netherlands, Switzerland, the U.S. and China. The U.S. facilities to be shut down include one in Princeton and another in Pittsburgh, the company said. More details about the wind down, including details pertaining to its timeline and costs, will be provided with the company’s full year earnings in February, it added.Galapagos CFO Aaron Cox had said in November that the company expects to be cash flow neutral to positive by the end of 2026 if the wind down is implemented.<h2 class="st-heading-2">Future After Wind Down</h2>On Monday, Galapagos said that the wind-down of the cell therapy activities will position it for longer-term growth. The company will continue to manage its non-cell therapy programs and evaluate all strategic alternatives for GLPG3667, an investigational, oral, selective inhibitor of tyrosine kinase 2, to accelerate its development in dermatomyositis and potentially other severe auto-immune indications, the company said.The company will also consider resuming the partnering process for the drug, it said. Galapagos also added that it will continue to maintain its presence at its headquarters in Belgium as well as its hubs in Chicago and San Francisco.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment about GLPG stayed in the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<a href="https://stocktwits.com/symbol/GLPG">GLPG stock</a> has gained 15% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/toyota-us-sales-rise-8-percent-in-q4/cmxMCZPR4Ri">US Heeds Trump To Buy A Toyota: Japanese Automaker’s US Sales Rise 8% In Q4</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A logo of Galapagos, a European pharmaceutical research company, is pictured outside its facility on June 9, 2020 in Leiden, Netherlands. (Photo by Yuriko Nakao/Getty Images) 

Galapagos Stock Rises After Hours On Starting To Wind Down Cell Therapy Activities, Subsequent Workforce Reduction 

The company had announced its intent to wind down the activities after a strategic review and sale process in October.

Equity

The company had announced its intent to wind down the activities after a strategic review and sale process in October.


<ul class="summary-bullets"><li>Brady said that the Prime members have received over €6 million in fare discounts, so “this trial has cost more money than it generates.”</li><li>All existing Prime members will continue to enjoy exclusive monthly low-fare offers until October 2026, but no new members will be allowed to sign up after Friday.</li><li>According to Ryanair’s website, the Prime members get free reserved seats, free travel insurance and access to 12 member-only seat sales and one each month.</li></ul>Ryanair (RYAAY) announced on Friday that it will close its prime member offering from November, following an eight-month trial period during which the European airline noted that the membership cost more than it generated.Chief Marketing Officer Dara Brady said that to date, Ryanair has signed up over 55,000 Prime members, generating over €4.4 million ($5.1 million) in subscription fees. However, Prime members have received over €6 million in fare discounts, so “this trial has cost more money than it generates,” Brady said,The company said that all existing Prime members will continue to enjoy exclusive monthly low-fare offers until October 2026, but no new members will be allowed to sign up after Friday.<h2 class="st-heading-2">Ryanair Prime Membership Details</h2>According to Ryanair’s website, Prime members get free reserved seats, free travel insurance, and access to 12 member-only seat sales, one each month. Prime members get the offer for £79 per annum.Ryanair noted that, based on a passenger who flew 12 times last year, the potential savings so far from the membership were £640 per year. The company added that for a passenger who flew three times last year, the potential savings so far were £415.<h2 class="st-heading-2">Brady’s View</h2>Brady noted that existing Prime members will be allowed to use their seat savings for the remainder of their 12-month membership.“This level of memberships, or subscription revenue does not justify the time and effort it takes to launch monthly exclusive Prime seat sales for our 55,000 Prime members,” Brady said.&nbsp;&nbsp;He noted that the airline has had over 207 million passengers this year and said that they would be trying to offer the lowest fares in Europe to&nbsp;all its customers, and not the subset of 55,000 Prime members.Retail sentiment on <a href="https://stocktwits.com/symbol/RYAAY">Ryanair</a> remained unchanged in the ‘bearish’ territory, with message volumes at ‘normal’ levels, according to data from Stocktwits.U.S.-listed shares of the company have gained nearly 57% this year.€1 = $1.16For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/abercrombie-fitch-catches-retail-attention-after-barclays-raises-price-target-on-hollister-momentum/cL5abTzRELe">Abercrombie &amp; Fitch Catches Retail Attention After Barclays Raises Price Target On Hollister Momentum</a>

Ryanair Boeing 737 MAX 8 as seen during taxiing, take off and flying phase in Eindhoven Airport.

Ryanair Pulls Plug On Prime Membership Offering After Trial Proves Too Costly 

Chief Marketing Officer Dara Brady said that to date, Ryanair has signed up over 55,000 prime members, generating over €4.4 million in subscription fees.

<ul class="summary-bullets"><li>Both subcutaneous and oral Amycretin appeared to have a safe and well-tolerated profile in the study, Novo said.</li><li>Novo is now planning to initiate a late-stage trial of Amycretin in patients with type 2 diabetes in 2026.&nbsp;</li><li>The positive announcement comes on the heels of the company's discontinuation of late-stage trials of its GLP-1 drug, Semaglutide, in Alzheimer’s disease.</li></ul> Novo Nordisk (NVO) on Tuesday said that a mid-stage trial evaluating Amycretin in people with type 2 diabetes yielded positive outcomes in both weight loss and reduction in average blood sugar levels.NVO shares traded 3% higher in the pre-market session at the time of writing.<h2 class="st-heading-2">Study Outcomes</h2>Amycretin showed statistically significant weight loss of up to 14.5% at 36 weeks, as compared to 2.6% in patients treated with placebo, and demonstrated statistically significant reductions in average blood sugar levels, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/25/3194155/0/en/Novo-Nordisk-phase-2-trial-with-amycretin-reports-significant-weight-loss-and-HbA1c-reduction-in-type-2-diabetes.html">said</a>.The trial investigated the efficacy, safety, and pharmacokinetics of once-weekly subcutaneous Amycretin and once-daily oral amycretin compared with placebo in 448 people with type 2 diabetes inadequately controlled on metformin. About 40% of the study participants also used a class of drugs known as SGLT2 inhibitors to manage their diabetes before joining the study.Amycretin belongs to the class of drugs known as GLP-1s, used to treat diabetes and obesity, similar to Novo’s blockbuster drugs Wegovy and Ozempic. Both subcutaneous and oral Amycretin appeared to have a safe and well-tolerated profile in the study, Novo said. The common side effects were gastrointestinal, and the vast majority were mild to moderate in severity, the company added.<h2 class="st-heading-2">Plans Ahead</h2>Novo is now planning to initiate a late-stage trial of Amycretin in patients with type 2 diabetes in 2026.Chief Scientific Officer Martin Holst Lange noted that this is the first time Amycretin has been evaluated in this population and added that the company is planning to test the GLP-1 compound across multiple indications starting next year.The positive announcement comes on the heels of the company's discontinuation of late-stage trials of its GLP-1 drug, Semaglutide, in Alzheimer’s disease.The company said on Monday that its late-stage trials evaluating oral Semaglutide in Alzheimer’s disease did not confirm its superiority over placebo in slowing disease progression, and it is subsequently discontinuing them.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NVO jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down by 48% this year and by about 57% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/autl-stock-soars-pre-market-on-position-recommendation-for-cell-therapy-targeting-cancer-in-uk/cL52LfPREXA">AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk’s Experimental GLP-1 Drug Shows Weight Loss, Blood Sugar Levels Reduction In Study

The trial was investigating the efficacy, safety, and pharmacokinetics of once-weekly subcutaneous amycretin and once-daily oral amycretin compared to placebo in 448 people with type 2 diabetes. 

<ul class="summary-bullets"><li>Semaglutide is the active ingredient in Novo’s blockbuster drugs Wegovy and Ozempic.&nbsp;</li><li>The company said it decided to test the drug in Alzheimer’s disease based on real-world evidence and preclinical models.</li><li>The company conducted two late-stage studies in Alzheimer’s disease, and while an improvement of disease-related biomarkers was observed in both trials with Semaglutide, it did not delay the progression of the disease.</li></ul>Novo Nordisk (NVO) on Monday said that its late-stage trials evaluating oral Semaglutide in Alzheimer’s disease did not confirm its superiority over placebo in slowing disease progression.Shares of the company slumped 11% in the pre-market session at the time of writingSemaglutide is the active ingredient in Novo’s blockbuster weight-loss drug Wegovy. The company said that it decided to test the drug in Alzheimer’s based on real-world evidence studies, pre-clinical models, as well as post-hoc analyses from diabetes and obesity trials. The compound, belonging to the category known as GLP-1 drugs, is marketed as Ozempic and Rybelsus for the treatment of type 2 diabetes as well.<h2 class="st-heading-2">Trial Outcomes</h2>The company conducted two late-stage studies in Alzheimer’s disease, and while an improvement of disease-related biomarkers was observed in both trials with Semaglutide, it did not delay the progression of the disease, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/24/3193328/0/en/Novo-Nordisk-A-S-Evoke-phase-3-trials-did-not-demonstrate-a-statistically-significant-reduction-in-Alzheimer-s-disease-progression.html">said</a>. The two trials enrolled a total of 3,808 adults and were aimed at evaluating the efficacy and safety of oral Semaglutide compared to placebo on top of standard of care in early-stage symptomatic Alzheimer’s disease.Alzheimer’s is a leading cause of memory loss or dementia. It is a progressive disease where symptoms gradually worsen over time. Semaglutide appears to have a safe and well-tolerated profile in the studies with patients aged 55-85 suffering from mild cognitive impairment or mild dementia due to Alzheimer’s disease, Novo noted.The company said that it is discontinuing the trials. However, the data generated will continue to provide benefits for individuals with type 2 diabetes, obesity, and related comorbidities, it added. The data from the trials will also be presented at future conferences, the company said.<h2 class="st-heading-2">Semaglutide And Its Many Indications</h2>Semaglutide is Novo's biggest asset. In the nine months through the end of September, the company reported sales of DKK 95.264 billion ($14.721.52 billion) from Ozempic, DKK 16.790 billion from Rybelsus and DKK 57.242 billion from Wegovy, togetherly accounting for about 74% of the company’s overall sales in the period.&nbsp;An approval in Alzheimer’s could have helped the company ramp revenue from the compound as its rivalry with American GLP-1 drugmaker Eli Lilly intensifies.&nbsp;The company’s drop in share price prompted a change in CEO earlier this year and layoffs.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NVO stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 45% this year and by 54% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/btc-holds-86000-crypto-market-back-above-3-trillion-xrp-doge-gain/cL5bex0REQP">Bitcoin Holds $86,000 With Crypto Market Back Above $3 Trillion – XRP, Doge Gain Ahead Of Grayscale’s New ETF Launches</a>For updates and corrections, email newsroom[at]stocktwits[dot]comExchange Rate: DKK1= $0.15

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk’s Blockbuster Drug Fails To Slow Alzheimer’s Disease Progression In Studies

The company said that it is discontinuing the trials.

BioNTech SE (BNTX) announced on Friday that a late-stage trial, conducted by its partner Duality Biologics in China, has met its primary endpoint of progression-free survival at a pre-specified interim analysis. The trial is evaluating Trastuzumab Pamirtecan versus Trastuzumab Emtansine in patients with certain types of breast cancer.Shares of the company traded 10% higher in the pre-market session on Friday. The <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.biontech.de/news-releases/news-release-details/biontech-and-dualitybio-announce-phase-3-trial-adc-candidate">trial</a> enrolled 228 patients with HER2-positive unresectable or metastatic breast cancer, an aggressive form of the disease that has spread and cannot be surgically removed, who previously received Trastuzumab and a taxane-based chemotherapy.On Stocktwits, retail sentiment around BNTX stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:577/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_05_at_8_57_36_AM_png_5a9988a80e.webp" alt="BNTX's Sentiment Meter and Message Volume as of 8:57 a.m. ET on Sept. 5, 2025 | Source: Stocktwits" width="577" height="60"><figcaption>BNTX's Sentiment Meter and Message Volume as of 8:57 a.m. ET on Sept. 5, 2025 | Source: Stocktwits</figcaption></figure> DualityBio now plans to discuss the next steps with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China regarding the submission of an application for Trastuzumab Pamirtecan approval.DualityBio Global Medical Officer Hua Mu noted that breast cancer has a high incidence rate in China, with over 350,000 new cases annually.“Together with our partner BioNTech, we plan the development of Trastuzumab Pamirtecan in further tumor types towards BLA application in other regions including the United States and the European Union to maximize its potential for patients around the world,” Mu said.BioNTech also noted that this is the first positive late-stage data readout achieved in the collaboration between the two companies initiated in April 2023. The collaboration aims to accelerate the development of differentiated antibody drug-conjugate therapeutics for solid tumors.BioNTech holds global commercial rights for Trastuzumab Pamirtecan, while DualityBio has commercial rights for Mainland China, Hong Kong Special Administrative Region, and Macau Special Administrative Region.BNTX stock is down by 9% this year but up by about 15% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-proposes-whopping-1-trillion-pay-package-for-ceo-elon-musk/chwIJkaRdpr">Tesla Proposes Whopping $1 Trillion Pay Package For CEO Elon Musk</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioNTech logo is displayed on a smartphone screen. (Photo illustration by Cheng Xin/Getty Images)

Why Did BioNTech Stock Surge 10% Pre-Market Today?

DualityBio now plans to discuss the next steps with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China regarding the submission of an application for Trastuzumab Pamirtecan approval.

Sanofi (SNY) announced on Thursday that its experimental drug, Amlitelimab, met all primary and key secondary endpoints in a late-stage study in adults and adolescents with atopic dermatitis (AD).The <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-09-04-05-00-00-3144170">study</a> enrolled 601 adults and adolescents aged 12 years and older with moderate-to-severe AD. Amlitelimab, dosed every four weeks or every 12 weeks, demonstrated statistically significant and clinically meaningful efficacy in skin clearance and disease severity compared to placebo at week 24. Furthermore, a progressive increase in efficacy was observed during the treatment period in patients who were dosed every four weeks as well as in those who were dosed every 12 weeks, the company said.The most common treatment-emergent adverse events, such as upper respiratory tract infection, were more common in the placebo arm compared to the Amlitelimab-treated arms of the study, it said.Shares of the company, however, traded 9% lower in the premarket session at the time of writing.According to a Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-sheds-13-billion-value-weak-trial-results-eczema-drug-2025-09-04/">report</a>, Jefferies analysts opined that the trial results fell short of those from an earlier trial and of rival biologic drugs. However, the drug's safety profile and convenient 12-week dosing regimen could still support its use.JPMorgan, meanwhile, noted that the data confirmed that Amlitelimab is less effective than Sanofi’s approved drug Dupixent, Reuters added. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SNY">SNY stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:578/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_04_at_7_50_44_AM_png_2f5aa98d10.webp" alt="SNY's Sentiment Meter and Message Volume as of 7:51 a.m. ET on Sept. 4, 2025 | Source: Stocktwits" width="578" height="61"><figcaption>SNY's Sentiment Meter and Message Volume as of 7:51 a.m. ET on Sept. 4, 2025 | Source: Stocktwits</figcaption></figure>Sanofi’s Dupixent is approved to treat atopic dermatitis in addition to asthma, chronic spontaneous urticaria, and other diseases. In the second quarter, Dupixent sales increased by 21.1% to €3.8 billion ($4.43 billion), and the company was expecting Amlitelimab to complement the blockbuster drug.The firm now looks forward to sharing additional late-stage results from the clinical development program of Amlitelimab in atopic dermatitis, said Houman Ashrafian, Executive Vice President, Head of Research &amp; Development at Sanofi.SNY stock is up 3% this year but down approximately 15% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/fda-says-no-advisory-commitee-meeting-required-for-aquestive-oral-epinephrine-film/chwd20pRdYB">FDA Says No Advisory Committee Meeting Needed For Aquestive’s Oral Epinephrine Film</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.Exchange Rate: €1= $1.17

Photo taken on April 15, 2025 shows the pharmaceutical factory of pharmaceutical company Sanofi in Hangzhou, Zhejiang province, China. (Photo credit should read CFOTO/Future Publishing via Getty Images)

Sanofi’s New Experimental Eczema Drug Meets Goals Of Late-stage Trial, But Wall Street Expected More

Amlitelimab, dosed every four weeks or every 12 weeks, demonstrated statistically significant and clinically meaningful efficacy in skin clearance and disease severity compared to placebo at week 24, the company said. 

A Delaware federal judge on Friday reportedly said that Novartis (NVS) cannot block India-based drugmaker MSN Pharmaceuticals from launching a generic version of its heart failure drug Entresto before its patent expires late next year.The judge rejected Novartis’ argument that the generic would infringe on one of the company’s patents, Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/litigation/novartis-loses-bid-block-us-entresto-generic-through-2026-2025-07-11/">reported</a>. U.S. District Judge Richard Andrews also denied Novartis’ request to block the generic from launching until after the patent expires in November 2026.NYSE-listed shares of <a href="https://stocktwits.com/symbol/NVS">Novartis</a> were trading 2% lower at the time of writing.Novartis told Reuters in a statement that it plans to appeal.The company told the court in a filing on Friday that MSN may receive the U.S. Food and Drug Administration’s approval for the generic as soon as July 16 and launch it soon after, cutting into the market for Entresto.Entresto is a prescription medicine used to treat adults with long-lasting (chronic) heart failure to help reduce the risk of death and hospitalization. It was Novartis’s best-selling brand in the first quarter.The company reported $2.26 billion in net sales for the drug, marking a growth of 22% at constant currency. The drug, in fact, accounted for over 17% of the company’s overall net sales in the period.The company said in April that the drug had sustained, robust, demand-led growth globally in the quarter, including in China and Japan, with increased penetration in hypertension.On Stocktwits, retail sentiment around Novartis remained unmoved in the ‘neutral’ territory over the past 24 hours while message volume stayed unchanged at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:622/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_11_at_2_12_01_PM_png_5d097b2dd4.webp" alt="NVS's Sentiment Meter and Message Volume as of 2:10 p.m. ET on July 11, 2025 | Source: Stocktwits" width="622" height="66"><figcaption>NVS's Sentiment Meter and Message Volume as of 2:10 p.m. ET on July 11, 2025 | Source: Stocktwits</figcaption></figure>NVS stock is up by about 25% this year and by about 10% over the past 12 months.Read Next: <a target="_blank" rel="noopener noreferrer nofollow" href="https://CMS’s Initial Proposal To Cover Renal Denervation A Win For Medtronic, Says Analysts">CEL-SCI Stock Soars On Imminent Partnership With Saudi Arabian Pharma Company For Cancer Drug: Retail’s Thrilled</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis Fails To Block Heart Failure Drug’s Generic From Launching Through 2026: Report

Novartis’ heart failure drug Entresto accounted for over 17% of the company’s overall net sales in the first quarter of 2025.

Novartis (NVS) on Tuesday said that Swiss authorities have approved its Coartem Baby as the first malaria medicine for newborns and young infants.<a href="https://stocktwits.com/symbol/NVS">Novartis</a> developed the treatment, also known as Riamet Baby in some geographies, in collaboration with Medicines for Malaria Venture (MMV).The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novartis.com/news/media-releases/novartis-receives-approval-first-malaria-medicine-newborn-babies-and-young-infants">said</a> that it now expects rapid approval for the treatment in eight African countries, including Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, Uganda, and Tanzania. &nbsp;Malaria is a life-threatening disease caused by a parasite and spread to humans by some types of mosquitoes. Novartis cited WHO data and noted that there were 263 million cases of malaria and 597,000 deaths in 2023, almost all of them in Africa.&nbsp;The company said it intends to introduce the infant-friendly treatment on a largely not-for-profit basis where malaria is endemic. According to Novartis, some 30 million babies are born in areas of malaria risk in Africa every year.The new approval is for the treatment of malaria in infants weighing between 2kg and 5kg. Novartis said there were no approved malaria treatments for infants weighing less than 4.5kg until now, leaving a treatment gap. Furthermore, malaria vaccines are also not approved for the youngest babies, the company noted.The pediatric formulation of the treatment is dissolvable, including in breast milk, and has a sweet cherry flavor to make it easier to administer.“The approval of Coartem Baby provides a necessary medicine with an optimized dose to treat an otherwise neglected group of patients and offers a valuable addition to the antimalarial toolbox,” CEO of MMV Martin Fitchet said.On Stocktwits, retail sentiment around Novartis is trending in the “bullish” territory, coupled with “high” message volume.<figure class="image"><img style="aspect-ratio:1250/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_08_at_7_32_02_AM_png_2a581d344f.webp" alt="NVS's Sentiment Meter and Message Volume as of 7:30 a.m. ET on July 8, 2025 | Source: Stocktwits" width="1250" height="130"><figcaption>NVS's Sentiment Meter and Message Volume as of 7:30 a.m. ET on July 8, 2025 | Source: Stocktwits</figcaption></figure>NVS stock is up by about 26% this year and by 13% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/musk-ally-isaacman-reacts-to-trump-s-political-jabs-says-nasa-without-a-confirmed-leader-not-ideal-for-america/chFvNyDR5g4">Musk Ally Isaacman Reacts To Trump’s Political Jabs, Says NASA Without A Confirmed Leader ‘Not Ideal For... America’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Novartis Gets Swiss Authority Nod For First Malaria Drug In Newborns, Young Infants

The company said that it now expects rapid approval for the treatment in eight African countries, including Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, Uganda, and Tanzania. 

Medicine company Novartis (NVS) said on Thursday that a late-stage trial evaluating its drug Cosentyx in adults with newly diagnosed or relapsing giant cell arteritis failed to meet its primary goal of sustained remission. &nbsp;Cosentyx was evaluated in combination with a 26-week steroid taper and compared to placebo plus a 52-week steroid taper in the trial. The drug, however, did not demonstrate a statistically significant improvement in sustained remission at week 52 compared to placebo.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-gcaptain-study-cosentyx-giant-cell-arteritis-gca">said</a> that it will share a full evaluation of the trial data at a later date.Shares of Novartis were trading 1% lower in the pre-market session.Giant cell arteritis (GCA) is the most common form of systemic vasculitis, a group of rare autoimmune diseases characterized by inflammation of blood vessels. GCA primarily affects people over 50 years of age and has the potential to cause irreversible vision loss and life-threatening aortic aneurysms.Cosentyx, launched in 2015, is already approved for use in adults with multiple conditions such as psoriatic arthritis, moderate to severe plaque psoriasis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa.It is also approved in pediatric patients with moderate to severe plaque psoriasis, enthesitis-related arthritis, and juvenile psoriatic arthritis.In the first quarter of 2025, Cosentyx brought in $1,534 million in net sales, marking a growth of 18% at constant currency, as sales grew mainly in the U.S., emerging markets, and Europe.Cosentyx, in fact, accounted for about 12% of the company’s overall net sales in the quarter.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVS">Novartis</a> jumped from ‘neutral’ to ‘bullish’ over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_03_082008_png_2cf306955c.webp" alt="NVS's Sentiment Meter and Message Volume as of 8:20 a.m. ET on July 3, 2025 | Source: Stocktwits" width="627" height="57"><figcaption>NVS's Sentiment Meter and Message Volume as of 8:20 a.m. ET on July 3, 2025 | Source: Stocktwits</figcaption></figure>NVS stock is up by over 27% this year and by about 16% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/alibaba-targets-1.5-billion-from-bond-sale-linked-to-health-arm/chFjAFkRcmI">Alibaba Targets $1.5B From Bond Sale Linked To Health Arm: Retail’s Buoyant</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Novartis’ Blockbuster Drug Fails Late-Stage Trial In Disease Causing Blood Vessel Inflammation, But Retail Turns Bullish

Giant cell arteritis (GCA) is the most common form of systemic vasculitis, a group of rare autoimmune diseases characterized by inflammation of blood vessels.

U.S. District Judge Mark Pittman in Fort Worth, Texas, reportedly upheld the U.S. Food and Drug Administration's (FDA) decision on Wednesday to remove Novo Nordisk's popular drugs, Ozempic and Wegovy, from its shortage list.Pittman said that the FDA had appropriately weighed supply and demand data for the drugs and properly removed them from the shortage list while rejecting a challenge brought by compounding pharmacies who sought to continue making copies of the drugs, Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-judge-upholds-fdas-removal-ozempic-wegovy-drug-shortage-list-2025-06-18/">reported</a>.Compounders are allowed to produce copies of drugs only when they are declared to be in short supply by the FDA. In February, the FDA announced that the semaglutide injection product shortage had been resolved, preventing compounders from manufacturing copies of Wegovy and Ozempic, as semaglutide is the active ingredient in them.Semaglutide injection products were first added to the FDA’s drug shortage list in 2022, paving the way for compounders to replicate them.Late last month, Novo Nordisk said that it had filed nearly 120 lawsuits across 34 states against compounders and other entities making false and misleading claims about their “semaglutide" drugs.The company also announced a $199-per-month limited-time offer for self-paying patients new to its weight loss drug, Wegovy, to encourage patients who previously used compounded versions of the drug to transition to Wegovy.On Stocktwits, retail sentiment around Novo Nordisk shares rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume fell from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:629/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_18_at_12_40_07_PM_png_8852be04e7.webp" alt="NVO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on June 18, 2025 | Source: Stocktwits" width="629" height="65"><figcaption>NVO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on June 18, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down by about 15% this year and by about 47% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tmc-stock-surges-to-near-4-year-high-after-opening-the-door-to-cashless-exercise-of-class-b-warrants/chlsB67RR2h">TMC Stock Surges To Near 4-Year High After Opening The Door To Cashless Exercise Of Class B Warrants</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

US Judge Upholds FDA Decision To Remove Wegovy, Ozempic From Shortage List In Move Against Compounding Pharmacies

The judge said that the FDA had appropriately weighed supply and demand data for the drugs and properly removed them from the shortage list, Reuters reported. 

Physical AI Infrastructure

Power & Energy to Support Growth

Healthcare Value & Innovation

Other – Comment Below

As markets head into 2026, investors are debating whether the next phase favors speculation or real-world execution. With capital rotating toward infrastructure, energy, and undervalued sectors like healthcare, which area do you think will matter most for portfolios in the year ahead?

Which Theme Will Matter Most for Portfolios in 2026?

APIE
Trust For Professional Managers - ActivePassive International Equity ETF

Feed

News

Sentiment

Fundamentals

Info

Latest APIE News

APIETrust For Professional Managers - ActivePassive International Equity ETF